HER2 Support Group Forums - View Single Post - Data Presented At San Antonio Breast Cancer Symposium Demonstrate Treatment With Deno

News · 12-11-2009, 07:10 AM

Amgen (NASDAQ:AMGN) announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer...

More...

12-11-2009, 07:10 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 20,109	Data Presented At San Antonio Breast Cancer Symposium Demonstrate Treatment With Deno Amgen (NASDAQ:AMGN) announced further detailed results from a Phase 3, head-to-head trial of denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer... More...